宁波韵升公告称，2026年第一次临时股东会于2月25日召开，由董事长竺晓东主持。本次会议审议了发 行H股股票并在港交所上市相关的16项议案，包括发行方案、募集资金使用、公司章程修订等。除选举 独立董事议案采取累积投票制外，其余议案表决均以现场和网络投票结合。结果显示，各议案同意股份 占比大多超99%，黄伟亮当选公司第十一届董事会独立董事。本次会议召集、召开程序及表决结果均合 法有效。 ...

Group 1 - The company, Shenzhen Xinlitai Pharmaceutical Co., Ltd., submitted an application for issuing H-shares and listing on the Hong Kong Stock Exchange on February 12, 2026 [1][2] - The application materials were published on the Hong Kong Stock Exchange website and are subject to updates and revisions as required by the Hong Kong Securities and Futures Commission and the Hong Kong Stock Exchange [1][2] - If the issuance and listing are implemented, the target investors will be limited to qualified foreign investors and domestic qualified investors authorized to conduct overseas securities investments according to Chinese laws and regulations [1][2] Group 2 - The announcement serves to inform domestic investors about the issuance and listing, and does not constitute an offer or invitation to purchase the H-shares [2] - The issuance and listing are subject to approvals from relevant government agencies and regulatory bodies, including the China Securities Regulatory Commission, the Hong Kong Securities and Futures Commission, and the Hong Kong Stock Exchange, indicating uncertainty in the process [2] - The company will fulfill its information disclosure obligations in accordance with the progress of the matter [2]

Group 1 - The company Tereader announced the convening of its sixth board meeting on January 22, 2026, to discuss the issuance of H-shares and listing on the Hong Kong Stock Exchange [1] - The meeting was held in Qingdao, combining both remote and in-person voting methods [1] Group 2 - Local state-owned assets are beginning to "bottom out" by purchasing auctioned properties, acquiring over 60 units in the Nansha District of Guangzhou at prices around 6,000 to 7,000 yuan per unit [1] - The average listing price for second-hand homes in the same community exceeds 20,000 yuan [1]

Meeting Overview - The first extraordinary general meeting of shareholders was held on January 16, 2026, in Shanghai [2] - The meeting was convened by the board of directors, with the chairman presiding and legal representatives present to witness the proceedings [2][9] Attendance and Voting - All six current directors and the board secretary attended the meeting, with some senior management participating via video [3][4] - There were no rejected proposals during the meeting [2] Resolutions Passed - The following key resolutions were approved: - Issuance of H-shares and listing on the Hong Kong Stock Exchange [5] - Various aspects of the H-share issuance, including location, type, timing, method, scale, pricing, and underwriting [6][7][8] - Transition to an overseas fundraising company [7] - Use of funds raised from the H-share issuance [7] - Validity period for the resolutions related to H-share issuance [7] - Authorization for the board to handle matters related to the H-share issuance [7] - Profit distribution plan prior to H-share issuance [8] - Appointment of auditing firms for the H-share issuance [8] - Amendments to the company’s articles of association post-H-share issuance [8] - Insurance for directors and senior management related to the issuance [8] - Determination of director roles [8] Legal Compliance - The meeting's procedures and resolutions were confirmed to be in compliance with relevant laws and regulations, as well as the company's articles of association [9]

Core Viewpoint - The company, Shanghai Longcheer Technology Co., Ltd., is in the process of issuing H-shares and listing on the Hong Kong Stock Exchange, with significant steps already taken towards this goal [1][2][3][4][5] Group 1: Application and Approval Process - On June 27, 2025, the company submitted its application for H-share issuance to the Hong Kong Stock Exchange [1] - The China Securities Regulatory Commission confirmed the company's overseas issuance and listing on December 9, 2025 [1] - The Hong Kong Stock Exchange held a listing hearing on December 17, 2025, to review the company's application [2] Group 2: H-share Offering Details - The total number of H-shares for global offering is set at 52,259,100 shares, with 5,226,000 shares allocated for public offering in Hong Kong, representing 10% of the total [4] - The company can issue up to an additional 7,838,800 shares through an over-allotment option, bringing the maximum total to 60,097,900 shares if fully exercised [5] - The expected price for the H-shares is capped at HKD 31 per share, with the public offering starting on January 14, 2026, and ending on January 19, 2026 [5] Group 3: Listing Timeline - The H-shares are anticipated to be listed and commence trading on the Hong Kong Stock Exchange on January 22, 2026 [5]

Group 1 - The company has canceled the first extraordinary general meeting of shareholders originally scheduled for January 9, 2026 [1][2] - The cancellation is due to the need to coordinate various work progress related to the issuance of H shares and listing [2] - The company will announce a new date for the shareholders' meeting to discuss the relevant proposals at a later time [2] Group 2 - The cancellation of the shareholders' meeting complies with relevant laws, regulations, and the company's articles of association [2] - The company expresses apologies for any inconvenience caused to investors and appreciates their understanding and support [2]

Core Viewpoint - The company held a shareholder meeting on November 17, 2025, where several key resolutions were passed, including the issuance of H-shares and amendments to the company's governance structure [2][10]. Meeting Details - The shareholder meeting was convened in Shanghai and was attended by all current directors and supervisors [3]. - The meeting utilized a combination of on-site and online voting methods, complying with relevant laws and the company's articles of association [2]. Resolutions Passed - The following key resolutions were approved: - Issuance of H-shares and listing on the Hong Kong Stock Exchange [4]. - Various aspects of the issuance, including types of shares, issuance timing, methods, scale, pricing, and underwriting [5][6]. - The plan for the use of funds raised from the H-share issuance [6]. - Amendments to the company's articles of association and internal governance rules [7][8]. - Approval of insurance for directors and senior management related to the listing [9]. - Reappointment of auditing firms for both A-shares and H-shares [9]. Voting Results - Resolutions 1-8 and 10 were special resolutions requiring over two-thirds approval, while other resolutions required a simple majority [9]. - The voting process was verified by legal representatives, confirming compliance with legal and regulatory requirements [10].

Core Viewpoint - Sichuan Baili Tianheng Pharmaceutical Co., Ltd. is in the process of issuing H-shares and listing on the Hong Kong Stock Exchange, with various steps completed in the application and approval process [1][2][3][4]. Group 1: Application and Approval Process - The company submitted its application for H-share issuance to the Hong Kong Stock Exchange on July 10, 2024, and published the application materials on the same day [2]. - The company resubmitted its application on January 21, 2025, and September 29, 2025, in accordance with the Hong Kong Stock Exchange's regulations [2]. - On December 11, 2024, the China Securities Regulatory Commission confirmed the company's application for overseas issuance and listing [3]. - The Hong Kong Stock Exchange's listing committee held a hearing on December 19, 2024, to review the company's application [3]. Group 2: H-share Offering Details - The total number of H-shares to be issued is 8,634,300, with 863,500 shares allocated for public offering in Hong Kong, representing approximately 10% of the total, and 7,770,800 shares for international offering, representing approximately 90% [6]. - The price range for the H-share issuance is preliminarily set between HKD 347.50 and HKD 389.00 [6]. - The public offering in Hong Kong commenced on November 7, 2025, and is expected to conclude on November 12, 2025, with the issuance price to be announced by November 14, 2025 [6]. - The H-shares are anticipated to be listed and commence trading on the Hong Kong Stock Exchange on November 17, 2025 [6].

Group 1 - The Chinese government emphasizes the need for a robust domestic economy and plans to enhance domestic demand and industry ecosystem [2] - The U.S. has implemented final measures in the 301 investigation against China's maritime, logistics, and shipbuilding sectors, leading to retaliatory actions from China against U.S. companies [2] - The People's Bank of China (PBOC) is expected to maintain a stable exchange rate and prevent excessive fluctuations, reinforcing the importance of market-driven exchange rate formation [4] Group 2 - The U.S. Federal Reserve Chairman Powell suggests a potential halt in the reduction of the balance sheet and indicates signs of tightening in the money market, with expectations of a rate cut later this month [3] - The latest data shows a steady increase in corporate sales revenue in China, with a year-on-year growth rate reaching 4.4% in the third quarter [5] - The Ministry of Industry and Information Technology (MIIT) is focusing on stabilizing growth in key industries and enhancing the application of artificial intelligence [4] Group 3 - The automotive industry in China has seen significant growth, with production and sales exceeding 3 million units for the first time in September, marking a year-on-year increase of 17.1% and 14.9% respectively [10] - The Hong Kong stock market has experienced substantial inflows from southbound capital, reaching a record high of 11,985.67 million HKD this year, despite recent adjustments [6] - Major companies like Mindray Medical and Shandong Gold are reporting significant profit increases, with Shandong Gold's net profit expected to rise by 83.9% to 98.5% year-on-year [9]

Group 1: Company Announcements - Mindray Medical plans to issue H-shares and list on the Hong Kong Stock Exchange, pending shareholder and regulatory approvals [1] - Shenghe Resources expects a net profit increase of 696.82% to 782.96% for the first three quarters of 2025, driven by favorable market demand and price increases for rare earth products [2] - Shandong Gold anticipates a net profit increase of 83.9% to 98.5% for the first three quarters of 2025, attributed to improved operational efficiency and rising gold prices [3] - Newray Materials reports significant stock price volatility, indicating potential market overreaction, although no fundamental changes have occurred [4] - Longbai Group's subsidiary has filed a lawsuit for technology infringement, with the amount involved totaling 1.311 billion yuan [5] - Chengdu Huami has launched a new RF transceiver chip, marking a significant breakthrough in its product line, although it is still in the early stages of market introduction [6] - Zhuhai Port has received approval from the CSRC to issue up to 1 billion yuan in technology innovation bonds [7] - Shengton Mining plans to acquire 100% of Canadian Loncor for approximately 1.9 billion USD, with core assets including a significant gold mining project in the Democratic Republic of Congo [8][9] Group 2: Financial Performance - Xiaogoods City reports a 100.52% increase in net profit for Q3 2025, with total revenue of 5.348 billion yuan, up 39.02% year-on-year [10] - Xianda Co. expects a net profit increase of 2807.87% to 3211.74% for the first three quarters of 2025, driven by rising prices of its main product [11] - Xianggang Technology anticipates a net profit increase of 182% to 200% for the first three quarters of 2025, supported by market expansion efforts [12] - Tongda Co. expects a net profit increase of 50.01% to 111.12% for the first three quarters of 2025, due to increased orders and delivery volumes [13] - Rockchip expects a net profit increase of 116% to 127% for the first three quarters of 2025, driven by growth in the AIoT market [14] - Jiantou Energy anticipates a net profit increase of 231.75% for the first three quarters of 2025, attributed to lower costs in its thermal power business [15] - Chongqing Steel expects a loss of 210 million to 230 million yuan for the first three quarters of 2025, an improvement from a loss of 1.35 billion yuan in the same period last year [16] - Yuanda Intelligent expects a net profit of 33.84 million to 50.74 million yuan for the first three quarters of 2025, recovering from a loss in the previous year [17] - China Metallurgical Group reports a 14.7% decline in new contracts signed in the first nine months of 2025, totaling 760.67 billion yuan, while overseas contracts increased by 10.1% [18]